mynth
04/2020100%

Glycom acquired by Royal DSM

DENMARK Life Sciences / Nutrition & Dietary Supplements EV €500M–1.5bn

Context

Royal DSM reached an agreement to acquire 100% of Glycom A/S. The strategic rationale for the acquisition is to accelerate DSM’s growth in the Early Life Nutrition (ELN) segment by adding HMOs (a novel, high-growth ingredient) to its portfolio. DSM intends to leverage its global sales force to offer Glycom’s HMOs to its broad customer base, reducing Glycom’s historical dependency on a single major customer (Nestlé). Furthermore, DSM aims to utilize its R&D and clinical competencies to speed up the development of next-generation HMOs and introduce these ingredients into new markets such as medical nutrition and pet food. The acquisition is expected to be highly synergetic, with DSM targeting an EBITDA contribution and EPS accretion of €0.10–€0.15 by 2021 as the "SaaS-like" recurring revenue from long-term supply contracts scales up.

Glycom, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2005, Glycom is the world's leading supplier of Human Milk Oligosaccharides (HMOs). HMOs are complex carbohydrates found in breast milk that act as essential prebiotics for infant immune and cognitive development. Glycom is the only fully integrated HMO provider globally, encompassing product development, preclinical/clinical research, and large-scale manufacturing at its state-of-the-art plant in Esbjerg, Denmark. The company pioneered the commercialization of HMOs for the Early Life Nutrition (ELN) market, with Nestlé serving as its primary long-term customer. Glycom’s value proposition lies in its unique IP portfolio and its "innovation roadmap" for next-generation HMOs. Its strategy focuses on providing high-purity, science-based ingredients that allow infant formula manufacturers to more closely mimic the nutritional profile of human breast milk.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

Above 6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2019
€50–100M
€25–50M
[members only]
2018
€50–100M
€25–50M
[members only]

Other operations with Royal DSM

Other operations with Royal DSM
DateAcquirerTargetCountrySector
09/2021ROYAL DSMFIRST CHOICE INGREDIENTSUNITED STATESIngredients
06/2020ROYAL DSMERBER GROUPAUSTRIAPetfood

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2020EQT PARTNERSSCHÜLKEGERMANYMedical Consumables
06/2020AVISTA CAPITAL PARTNERSVISION HEALTHCAREBELGIUMNutrition & Dietary Supplements
04/2020WARBURG PINCUSPOLYPLUSFRANCER&D Biotech
04/2020AMERICAN SECURITIESPARAGON MEDICALUNITED STATESMedical Devices
03/2020LBO FRANCEDUTSCHERFRANCEMedical Consumables
02/2020TETHYS INVEST / PSP INVESTMENTS / MITSUI & COCEVA SANTE ANIMALEFRANCEAnimal Health
02/2020PERRIGO COMPANYHIGH RIDGE BRANDS (ORAL CARE PORTFOLIO)UNITED STATESGenerics / Labs
10/2019DENTRESSANGLEMARLE GROUPFRANCEImplants & Prosthetics
09/2019SAGARDSTERIMEDFRANCEMedical Consumables
08/2019PERMIRACAMBREX CORPORATIONUNITED STATESCDMO

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €50–100M

EBITDA range: €25–50M

EV/Revenue range: Above 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Glycom by Royal DSM are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Royal DSM’s acquisition of 100% of Glycom, a Danish company specialised in Nutrition & Dietary Supplements, in 2020.

How was the acquisition of Glycom by Royal DSM valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the Above 6x range. Exact figures are available to members.

What were Glycom’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Glycom generated annual revenue estimated in the €50–100M range and EBITDA in the €25–50M bracket (FY 2019). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.